Immunocore Holdings plcIMCREarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.
IMCR Q4 FY2025 Key Financial Metrics
Revenue
$104.5M
Gross Profit
$101.8M
Operating Profit
$-19.7M
Net Profit
N/A
Gross Margin
97.4%
Operating Margin
-18.8%
Net Margin
N/A
YoY Growth
24.3%
EPS
$-0.61
Immunocore Holdings plc Q4 FY2025 Financial Summary
Immunocore Holdings plc reported revenue of $104.5M (up 24.3% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $2.7M, operating expenses totaled $121.5M.
Key Financial Metrics
| Total Revenue | $104.5M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 97.4% |
| Operating Margin | -18.8% |
| Report Period | Q4 FY2025 |
Immunocore Holdings plc Annual Revenue by Year
Immunocore Holdings plc annual revenue history includes year-by-year totals (for example, 2025 revenue was $400.0M).
Immunocore Holdings plc Quarterly Revenue & Net Profit History
Immunocore Holdings plc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $104.5M | +24.3% | N/A | N/A |
| Q3 FY2025 | $103.7M | +29.2% | $-177.0K | -0.2% |
| Q2 FY2025 | $98.0M | +29.9% | $-10.3M | -10.5% |
| Q1 FY2025 | $93.9M | +33.2% | $5.0M | 5.4% |
| Q4 FY2024 | $84.1M | — | N/A | N/A |
| Q3 FY2024 | $80.2M | — | $8.7M | 10.9% |
| Q2 FY2024 | $75.4M | +26.2% | $-11.6M | -15.4% |
| Q1 FY2024 | $70.5M | — | $-24.4M | -34.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $70.5M | $75.4M | $80.2M | $84.1M | $93.9M | $98.0M | $103.7M | $104.5M |
| YoY Growth | N/A | 26.2% | N/A | N/A | 33.2% | 29.9% | 29.2% | 24.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $994.0M | $1.02B | $1.08B | $1.01B | $1.03B | $1.08B | $1.10B | $1.07B |
| Liabilities | $634.5M | $664.2M | $706.8M | $648.8M | $649.5M | $693.9M | $705.9M | $686.2M |
| Equity | $359.5M | $359.1M | $377.8M | $360.7M | $378.5M | $388.5M | $396.6M | $381.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.6M | $23.5M | $21.1M | $-14.0M | $435000 | $26.0M | $-4.5M | $-32.7M |